Azitra (AZTR) Net Cash Flow (2022 - 2026)
Azitra (AZTR) reported Net Cash Flow of $8.0 million for Q1 2026, up 692.2% on a YoY basis from $1.0 million in Q1 2025, and up 1098.27% quarter-over-quarter from $666205.0 in Q4 2025.
Azitra (AZTR) Net Cash Flow (2022 - 2026) Analysis & Trends
Azitra has reported Net Cash Flow for 5 years, with the latest figure at $8.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 692.2% year-over-year to $8.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.8 million (up 3229.71% YoY), and the FY2025 full-year result was -$2.5 million, down 190.14% from the prior year.
- Net Cash Flow for Q1 2026 stood at $8.0 million, up from $666205.0 in the prior quarter.
- The five-year high for Net Cash Flow was $8.0 million in Q1 2026, with the low at -$2.7 million in Q4 2024.
- Historically, Net Cash Flow has averaged $419977.9 across 5 years, with a median of -$1.3 million in 2025.
- Annual changes were most pronounced in 2025 — Net Cash Flow plunged 211.85% — and 2026, when it soared 692.2%.
- Azitra's Net Cash Flow stood at -$2.4 million in 2022, then declined by 6.49% to -$2.6 million in 2023, then slipped by 3.88% to -$2.7 million in 2024, then soared by 124.62% to $666205.0 in 2025, then jumped by 1098.27% to $8.0 million in 2026.
- The last three Net Cash Flow figures came in at $8.0 million (Q1 2026), $666205.0 (Q4 2025), and $369350.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 664,983.53 |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | 7.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.98 Mn |
| Mar 31, 2026 | 7.98 Mn |
| Dec 31, 2025 | 666,205.00 |
| Dec 31, 2025 | 666,205.00 |
| Sep 30, 2025 | 369,350.00 |
| Sep 30, 2025 | 369,350.00 |
| Jun 30, 2025 | -2.17 Mn |
| Jun 30, 2025 | -2.17 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Dec 31, 2024 | -2.71 Mn |
| Dec 31, 2024 | -2.71 Mn |
| Sep 30, 2024 | 6.46 Mn |
| Sep 30, 2024 | 6.46 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Dec 31, 2023 | -2.60 Mn |
| Dec 31, 2023 | -2.60 Mn |